Biosergen AS Cash Flow Conversion Efficiency
Biosergen AS cash flow conversion efficiency. Based on the latest financial reports, Biosergen AS (BIOSGN) has a cash flow conversion efficiency ratio of -0.954x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.75 Million ≈ $-833.70K USD) by net assets (Skr8.12 Million ≈ $873.52K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biosergen AS (2019–2025)
Cash flow conversion efficiency of Biosergen AS from 2019 to 2025. This chart illustrates how Biosergen AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Biosergen AS for real-time trading data and today's change.
Biosergen AS Cash Flow Conversion Ratio Explained
Biosergen AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biosergen AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biosergen AS ranked by their cash flow conversion efficiency. Also see Biosergen AS (BIOSGN) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Haydale Graphene Industries
LSE:HAYD
|
-0.398x |
|
Enlivex Therapeutics Ltd
TA:ENLV
|
-0.131x |
|
Lexington Gold Ltd
LSE:LEX
|
-0.028x |
|
Safe Orthopaedics SA
PA:ALSAF
|
0.143x |
|
The Investment Company plc
LSE:INV
|
-0.009x |
|
Sumo Resources PLC
PA:MLSUM
|
N/A |
|
IQ-AI LTD. LS -01
F:5Y1
|
N/A |
|
Marlowe plc
LSE:MRL
|
0.184x |
Annual Cash Flow Conversion Efficiency for Biosergen AS (2019–2025)
The table below shows the annual cash flow conversion efficiency of Biosergen AS from 2019 to 2025. Review cash generation quality of Biosergen AS to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr8.12 Million ≈ $873.52K |
Skr-35.53 Million ≈ $-3.82 Million |
-4.378x | -1193.49% |
| 2024-12-31 | Skr49.14 Million ≈ $5.29 Million |
Skr-16.63 Million ≈ $-1.79 Million |
-0.338x | +97.80% |
| 2023-12-31 | Skr2.12 Million ≈ $227.72K |
Skr-32.60 Million ≈ $-3.51 Million |
-15.408x | -1092.92% |
| 2022-12-31 | Skr22.79 Million ≈ $2.45 Million |
Skr-29.44 Million ≈ $-3.17 Million |
-1.292x | +30.77% |
| 2021-12-31 | Skr20.23 Million ≈ $2.18 Million |
Skr-37.75 Million ≈ $-4.06 Million |
-1.866x | -544.61% |
| 2020-12-31 | Skr-10.92 Million ≈ $-1.18 Million |
Skr-4.58 Million ≈ $-493.31K |
0.420x | -14.94% |
| 2019-12-31 | Skr-4.69 Million ≈ $-504.90K |
Skr-2.31 Million ≈ $-249.07K |
0.493x | -- |
About Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.